HS-20122

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameHS-20122
Drug Alias NameHS-20122HS20122
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Hansoh Biomedical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co LtdChangzhou Hengbang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A